Doug Bates

As of January 2, 2014, Apredica, LLC will change its name to Cyprotex US, LLC (trading as “Cyprotex”). You may be aware that we are currently investing heavily in our US site in Watertown near Boston to replicate our hugely successful high throughput ADME facility which we originally developed at our Macclesfield, UK site. The intended launch of this facility is January 2014. As the service portfolios between the sites become more aligned, we feel that it is the right time to unify the brands under the Cyprotex name. This will help us to expand the Cyprotex brand globally and help reduce any confusion in the market. In terms of how you work with us, very little will change. The legal entity remains the same so all existing documents such as service agreements, confidentiality agreements, work orders and open invoices will remain in force. If your internal procedures require a formal novation of the documentation, please let me know and our Legal Counsel will do what is necessary to meet your procedures. With the exception of the company name, our bank details and VAT numbers will not change. I would be grateful if your Accounting Department could be advised of the change of name to avoid any confusion in the finance function. Outwardly, the most noticeable impact will be that the Apredica website will no longer be accessible and all information on the company will be accessed on the Cyprotex website www.cyprotex.com. We do not anticipate that the name change will impact on the way you work with our company. However, if you have any concerns or questions about the change then please let me know and I will be happy to address them. Kind Regards Anthony Baxter PhD Chief Executive Officer Cyprotex E-mail: a.baxter@cyprotex.com Tel: +44 (0)1625 505146